Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

EU nod for BioMarin’s second PKU therapy Palynziq

EU nod for BioMarin’s second PKU therapy Palynziq BioMarin has identified Palyniq as having potential to break through the annual $1bn sales mark, but analysts forecast this to be nearer $500m. ... This strategy is in line with BioMarin’s most promising late-stage candidate, valoctocogene

#OrkambiNow?

#OrkambiNow? But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and

Sangamo surges on data for haemophilia A gene therapy

Sangamo surges on data for haemophilia A gene therapy The new data would seem to put SB-525 firmly in contention with two other haemophilia A gene therapies that have been generating clinical data, namely valoctocogene roxaparvovec (valrox) from BioMarin ... therapies. BioMarin is currently thought to be

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma Meanwhile, BioMarin got the nod for Palynziq (pegvaliase), a new enzyme replacement therapy for patients aged 16 and older with phenylketonuria, a rare but potentially serious inherited metabolic disease.

Roche buys gene therapy specialist Spark for $4.3bn

Roche buys gene therapy specialist Spark for $4.3bn It’s facing of competition in this area though, with BioMarin’s valoctocogene roxaparvovec also in phase 3 testing for haemophilia A and looking like it could be first to market

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics